Alger

Impulse Dynamics is a medical device company offering innovative solutions for the treatment of chronic heart failure. Its CCM® therapy is specifically designed to improve the contraction of the heart to deliver more oxygen-rich blood to the body. The therapy is a safe and effective minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them.

Weatherbie Capital was founded in 1995 by Matthew Weatherbie and, similar to Alger, takes a fundamental, bottom-up research approach to investing in growth equities. Weatherbie Capital aims to identify and invest in attractive U.S. small- and mid-cap companies poised for growth. The firm’s flagship strategy, the Weatherbie Specialized Growth strategy, has, for its 20-plus years in existence, demonstrated a record of strong relative performance. Mr. Weatherbie will remain CEO and, again become Co-CIO, of Weatherbie Capital, which at closing, will become a wholly owned subsidiary of Alger.

Prosetta Corporation operates as a biopharmaceutical company in the United States. It focuses on applied science. The company was founded in 2002 and is based in San Francisco, California.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has created a range of products targeting various signaling pathways involved in disease progression. Notable therapeutics include TP-0413, which addresses serum iron regulation in chronic inflammatory diseases; TP-0903, a dual-targeted agent for pancreatic cancer; and TP-0829, aimed at treating B-cell lymphomas and leukemia. Other developments include TP-0227, targeting pathways in endometrial carcinomas, and TP-1149, which aims to overcome resistance in myeloma cells. Tolero Pharmaceuticals is dedicated to improving patient outcomes through innovative approaches and has established a strategic partnership with MannKind Corporation to further its mission.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has created a range of products targeting various signaling pathways involved in disease progression. Notable therapeutics include TP-0413, which addresses serum iron regulation in chronic inflammatory diseases; TP-0903, a dual-targeted agent for pancreatic cancer; and TP-0829, aimed at treating B-cell lymphomas and leukemia. Other developments include TP-0227, targeting pathways in endometrial carcinomas, and TP-1149, which aims to overcome resistance in myeloma cells. Tolero Pharmaceuticals is dedicated to improving patient outcomes through innovative approaches and has established a strategic partnership with MannKind Corporation to further its mission.

ChoiceStream is a programmatic advertising partner that runs cross-device branding and direct response campaigns for brand and agency clients. ChoiceStream manages each phase of a campaign, from pre-launch planning to completion. By collecting poll-based, proprietary data specific to each client’s campaign, ChoiceStream creates custom, targetable audiences, optimizes results in real-time, and provides unique audience insight throughout each campaign. With world-class machine-learning algorithms and a dedicated team of in-house industry experts, ChoiceStream boasts an 83% client retention rate - well above the industry average. This combination of innovative technology and personalized service ensures that clients achieve their desired metrics. For more information on ChoiceStream,

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.